Strs Ohio Invests $257,000 in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Strs Ohio bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the fourth quarter, Holdings Channel reports. The institutional investor bought 17,500 shares of the company’s stock, valued at approximately $257,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMLX. SG Americas Securities LLC raised its stake in shares of Amylyx Pharmaceuticals by 155.5% in the 3rd quarter. SG Americas Securities LLC now owns 21,255 shares of the company’s stock valued at $389,000 after buying an additional 12,936 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Amylyx Pharmaceuticals by 16.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,134 shares of the company’s stock worth $112,000 after purchasing an additional 859 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Amylyx Pharmaceuticals by 3.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,254 shares of the company’s stock worth $444,000 after purchasing an additional 905 shares during the period. Emerald Advisers LLC boosted its holdings in Amylyx Pharmaceuticals by 0.8% during the third quarter. Emerald Advisers LLC now owns 838,572 shares of the company’s stock valued at $15,354,000 after purchasing an additional 6,764 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Amylyx Pharmaceuticals by 41.1% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 49,566 shares of the company’s stock worth $908,000 after buying an additional 14,427 shares during the period. 95.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on AMLX shares. Robert W. Baird lowered Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, March 11th. Leerink Partnrs downgraded Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. SVB Leerink lowered Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Monday, April 8th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $32.67.

Amylyx Pharmaceuticals Stock Up 8.0 %

AMLX stock opened at $1.90 on Tuesday. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.70 and a twelve month high of $30.50. The company has a market cap of $129.22 million, a P/E ratio of 2.71 and a beta of -0.92. The business has a fifty day moving average of $6.63 and a 200-day moving average of $12.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The firm had revenue of $108.45 million during the quarter, compared to analysts’ expectations of $106.40 million. Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. During the same period in the previous year, the business posted ($0.65) EPS. As a group, equities research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.01 earnings per share for the current fiscal year.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 4,135 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $77,448.55. Following the completion of the sale, the chief executive officer now owns 3,023,002 shares in the company, valued at approximately $56,620,827.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO James M. Frates sold 1,792 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total transaction of $33,564.16. Following the completion of the transaction, the chief financial officer now directly owns 134,784 shares in the company, valued at approximately $2,524,504.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua B. Cohen sold 4,135 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $77,448.55. Following the completion of the sale, the chief executive officer now directly owns 3,023,002 shares of the company’s stock, valued at $56,620,827.46. The disclosure for this sale can be found here. Insiders have sold 10,305 shares of company stock worth $193,098 over the last ninety days. Company insiders own 11.80% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.